LipoSeuticals, Inc. (LSI), a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of parenteral drug products based on its proprietary and novel drug delivery technology, announced today that it recently closed a financing round for an undisclosed amount led by Delos Capital, a Hong Kong based life sciences fund.
Founded in 2012, LSI has developed a patented sugar-lipid polymer-based formulation platform, Sulocence® - a unique drug delivery technology that enhances drug stability and solubility. LSI is currently applying the sugar-lipid technology to the reformulation of a number of marketed specialty drugs. LipoSeuticals has a robust drug pipeline of drug candidates addressing unmet medical needs in significant markets.
Dr. Lan Bo Chen, who will be joining LSI's Board representing Delos Capital, commented that, "This exciting opportunity enables the LSI management team and Delos to embark on our stated mission of building a premier specialty pharmaceutical company that will develop, manufacture and market proprietary branded formulations of select known drug products. We intend to leverage our deep and strong relationships in the pharmaceutical arena and invest wisely in manufacturing facilities, R&D laboratories and the robust drug pipeline under development at LipoSeuticals in order to build and grow a world-class pharmaceutical organization."
Dr. Nian Wu, founder and inventor of the Sulocence® technology platform and the Company's Chief Executive Officer, stated, "I am extremely proud of the company that we have built over the course of the past five years with the help of the entire LSI team of scientists and staff. We are delighted that we now have the expertise and financial resources to build on LSI's solid foundation. Our Sulocence® technology has tremendous potential for improving many drug products that currently suffer from poor solubility, stability, and side effects. We are confident that with the help of Delos' financial resources, experience and strong relationships within the Life Science Industry, we will achieve sustainable success."
About LipoSeuticals, Inc.
LipoSeuticals, Inc. is a specialty pharmaceuticals firm focused on the development of next-generation proprietary formulations of sterile injectable drugs, principally aimed at the domains of anesthesiology, oncology and infectious disease. The firm has developed a revolutionary approach to the formulation of non-water-soluble drugs, which enables the creation of products with greater stability, superior shelf life, improved ease of manufacturing and enhanced safety. The firm's pipeline is specifically geared towards development via the 505(b)(2) pathway at the United States Food and Drug Administration (FDA), which substantially expedites the development, review and approval timeline. LipoSeuticals also seeks to extend the commercial window of its products through the generation of novel intellectual property and other regulatory exclusivity available via the Hatch-Waxman Act.
About Delos Capital
Delos Capital is a healthcare-focused fund that invests in growth platforms in Greater China and innovation in the US in the areas of therapeutics and medical technology. Delos Capital seeks to achieve returns through supporting these companies in their development and also helping to create additional value from collaboration between these companies. Founded in 2014, Delos Capital operates from its main office in Hong Kong.